Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 114 results found. Search for [ covaxin efficacy data ]

Results 1 to 21 of 114
BusinessToday.In
April 28, 2021
\"Initial positive neutralisation studies of B.1.617, with both post-Covaxin or Covishield sera, are correlatable with milder disease during post-vaccination breakthrough infections,\" says Anurag Agrawal, Director, Institute of Genomics and Integrative Biology


PTI
April 28, 2021
Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on January 3


BusinessToday.In
April 25, 2021
The Hyderabad-based vaccine manufacturer has submitted updated accelerated and real-time stability data of Coaxin along with the justification for the extension of shelf life


BusinessToday.In
April 24, 2021
At these rates, Covaxin will be twice as costly as Covishield, which will be sold to state governments at Rs 400 per dose and to private hospitals at Rs 600 per dose in Phase 3 of vacccination drive


BusinessToday.In
April 21, 2021
The new variant, B.1.618 is also called a major immune escape variant, as it can escape immunity even if a person has contracted the virus before and can produce antibodies against it


Joe C Mathew
April 21, 2021
\"Efficacy against SARS-Cov-2 has been established. COVAXIN has demonstrated an excellent safety record in human clinical trials and in usage under emergency use,\" said Dr Krishna Ella, MD & Chairman, Bharat Biotech


BusinessToday.In
April 14, 2021
Coronavirus vaccination: After taking the first shot, the vaccine beneficiary will receive a message on his/her registered mobile number about the link to download the vaccination certificate


BusinessToday.In
April 13, 2021
Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev added that Sputnik V's production at a larger scale will start by July 2021 with plans to produce 500 million doses


BusinessToday.In
April 13, 2021
India is the leading production hub for Sputnik V. RDIF has signed pacts with Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech to produce over 850 million doses per year


BusinessToday.In
April 12, 2021
Developed by Russia's Gamaleya national center of epidemiology and microbiology, Sputnik V is the third COVID-19 vaccine approved by the Subject Expert Committee (SEC) after Covishield and Covaxin


BusinessToday.In
April 12, 2021
Of around 20 coronavirus vaccines in several clinical and pre-clinical stages, Russia's Sputnik V may get SEC's nod first


BusinessToday.In
April 11, 2021
Russian Direct Investment Fund (RDIF) has tied up with a host of Indian pharma companies such as Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the production of Sputnik V


BusinessToday.In
March 27, 2021
SII has signed an agreement with Novavax to manufacture a vaccine with the name 'Covovax' in India. Novavax has announced final efficacy of 96.4 per cent against original COVID-19 virus. Novavax with Serum will provide 1.1 billion cumulative doses for COVAX Facility


BusinessToday.In
March 24, 2021
Already the Russian Direct Investment Fund, the force behind the Russian vaccine, has signed deals with several Indian companies for the production and distribution of Sputnik V


BusinessToday.In
March 12, 2021
Denmark suspended the AstraZeneca Covid-19 vaccine on Thursday after many recipients reported blood clotting and one among them has allegedly \"died\". Norway and Iceland also followed the suit, scrapping the vaccine administration


Reuters
March 10, 2021
The US company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with Germany's BioNTech SE, out of one of the world's biggest drug markets


BusinessToday.In
March 4, 2021
In order to ramp up the COVID-19 vaccination capacity, the government is involving a large number of private facilities. The health ministry had said that around 10,000 hospitals under Ayushman Bharat-PMJAY and 687 hospitals under CGHS can be used as CVCs


PTI
March 4, 2021
The high court also asked the Centre to explain in affidavit the rationale behind keeping strict control over class of persons who can be vaccinated against COVID-19


BusinessToday.In
March 4, 2021
Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus


BusinessToday.In
March 4, 2021
Union Finance Minister Nirmala Sitharaman got first dose of the COVID-19 vaccine today; shares image of herself getting vaccinated on Twitter


PAGES 1 OF 6  12345